Trial Suggests Bimekizumab Effective in Clear Skin Management

August 9, 2021
Armand Butera

Armand Butera is the assistant editor for HCPLive. He attended Fairleigh Dickinson University and graduated with a degree in communications with a concentration in journalism. Prior to graduating, Armand worked as the editor-in-chief of his college newspaper and a radio host for WFDU. He went on to work as a copywriter, freelancer, and human resources assistant before joining HCPLive. In his spare time, he enjoys reading, writing, traveling with his companion and spinning vinyl records. Email him at abutera@mjhlifesciences.com.

An ongoing study of the IL-17A and IL-17F inhibitor showed patients with moderate to severe plaque psoriasis achieved long-term skin clearance results.

New data from the BE BRIGHT open-label extension trial with bimekizumab showed that 9 out of 10 patients with moderate to severe plaque psoriasis who achieved clear or almost clear skin after 16 weeks of treatment maintained these responses through to 2 years with continued dosing.

Additionally, over 8 out of 10 patients with moderate to severe plaque psoriasis who achieved complete skin clearance (PASI 100) at week 16 also maintained PASI 100 responses through to 2 years of treatment with continued dosing.

Bimekizumab is an investigational IL-17A and IL-17F inhibitor, the safety, tolerability, and efficacy of which was studied over a 2-year trial period by global biopharmaceutical company UCB.

Clear skin was measured using the Investigator’s Global Assessment (IGA) of Clear or Almost Clear skin (IGA 0/1)

The study was comprised of 989 patients, some of whom completed previous evaluations in the Phase 3 studies of bimekizumab, including BE VIVID, BE READY, and BE SURE. At week 16, 87.5% achieved IGA 0/1, 74.9% achieved BSA ≤1% and 62.7% achieved PASI 100.

Results from the trial were presented at the 2021 American Academy of Dermatology (AAD) Summer Meeting, Tampa, Florida.

“These interim results from the BE BRIGHT study highlight the potential of bimekizumab to provide lasting skin clearance to adults living with moderate to severe plaque psoriasis,” said Mark Lebwohl, MD, Dean for Clinical Therapeutics, Icahn School of Medicine at Mount Sinai, and Chairman emeritus, Kimberly and Eric J. Waldman Department of Dermatology and Presenting Author of the data at the AAD Summer Meeting.

“These data are meaningful for the dermatology community and further add to the clinical evidence we have from the bimekizumab Phase 3 clinical program.”

Though the efficacy and safety of bimekizumab have not been established and it is not approved by any regulatory authority worldwide, the inhibit is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in adults.


x